Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2025 Earnings Guidance

Key Points

• Halozyme Therapeutics has issued updated earnings guidance for FY 2025, projecting earnings per share between 6.000 and 6.400, exceeding the consensus estimate of 5.500, along with revenue expectations of $1.3 billion to $1.4 billion.
• Following the announcement, shares of HALO saw an uptick of 1.4% during trading hours, reaching $60.81, with a market capitalization of $7.49 billion.
• Analysts are mixed on Halozyme's stock; while some maintain a "buy" rating, others have downgraded their ratings, leading to an average stock rating of "Hold" with a consensus target price of $62.70.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 6.000-6.400 for the period, compared to the consensus estimate of 5.500. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, May 29th. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. JPMorgan Chase & Co. increased their target price on shares of Halozyme Therapeutics from $58.00 to $60.00 and gave the stock a "neutral" rating in a report on Wednesday, July 16th. Finally, Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $73.00 to $62.00 in a report on Wednesday, May 14th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $62.70.

Halozyme Therapeutics Stock Up 1.4%

Shares of HALO stock traded up $0.82 during trading hours on Tuesday, hitting $60.81. 3,136,809 shares of the company were exchanged, compared to its average volume of 1,931,695. The company has a market capitalization of $7.49 billion, a PE ratio of 16.17, a PEG ratio of 0.39 and a beta of 1.17. Halozyme Therapeutics has a 52 week low of $42.01 and a 52 week high of $70.50. The business has a 50 day moving average of $55.40 and a two-hundred day moving average of $57.78. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.47 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.25. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. Analysts anticipate that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at $41,403,763.17. This trade represents a 2.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 60,000 shares of company stock valued at $3,262,400 over the last ninety days. 2.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Halozyme Therapeutics stock. Acadian Asset Management LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 3,056 shares of the biopharmaceutical company's stock, valued at approximately $195,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.